SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

SRT3

215.05

-3.76%↓

ORNBV.FI

68.55

+0.07%↑

PHMA

95.6

-1.49%↓

DRW3

89.85

-0.88%↓

Home・Elenco Azioni・Sanofi SA

Search

Sanofi SA

Chiusa

SettoreSettore sanitario

73.045 -1.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

72.74

Massimo

73.07

Metriche Chiave
By Trading Economics
Entrata	-394M 1.6B
Vendite	-12B 11B
P/E Media del settore	20.158 49.8
EPS	1.34
Margine di Profitto	14.354
Dipendenti	74,846
EBITDA	1.5B 2.7B

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+28.18% upside

Dividendi
By Dow Jones
Utili prossimi	30 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-5.1B 94B
Apertura precedente	74.48
Chiusura precedente	73.045

Notizie sul Sentiment di mercato

By Acuity

39%

61%

118 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

91.3 / 96.1 Supporto e resistenza

Sanofi SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 09:03 UTC

Utili

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

29 apr 2026, 05:27 UTC

Utili

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

23 apr 2026, 06:12 UTC

Utili

Sanofi Posts Higher Sales Amid Leadership Transition

7 mag 2026, 06:47 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

1 mag 2026, 06:14 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

1 mag 2026, 06:13 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

1 mag 2026, 06:12 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK Financed Deal From Existing Cash Resources

1 mag 2026, 06:08 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK Announced Key Terms of Deal July 2025

1 mag 2026, 06:03 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK Buys TSB Banking for GBP2.65B

1 mag 2026, 06:02 UTC

Acquisizioni, Fusioni, Takeovers

Santander UK Buys TSB Banking Group

29 apr 2026, 12:01 UTC

Utili

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

29 apr 2026, 06:27 UTC

Discorsi di Mercato

Utili

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

29 apr 2026, 04:55 UTC

Utili

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

29 apr 2026, 04:55 UTC

Utili

Santander 1Q Loan Loss Provisions EUR3.225B

29 apr 2026, 04:54 UTC

Utili

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

29 apr 2026, 04:54 UTC

Utili

Santander 1Q Operating Expenses EUR6.48B

29 apr 2026, 04:52 UTC

Utili

Santander Backs 2028 View

29 apr 2026, 04:52 UTC

Utili

Santander Backs 2026 View

29 apr 2026, 04:52 UTC

Utili

Santander 1Q Underlying RoTE 15.2%

29 apr 2026, 04:51 UTC

Utili

Santander End-1Q CET1 Ratio 14.4%

29 apr 2026, 04:51 UTC

Utili

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

29 apr 2026, 04:51 UTC

Utili

Santander 1Q Net Interest Income EUR11.02B

29 apr 2026, 04:50 UTC

Utili

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

29 apr 2026, 04:50 UTC

Utili

Santander 1Q Underlying Pft EUR3.56B

29 apr 2026, 04:49 UTC

Utili

Santander 1Q Net Pft EUR5.455B

29 apr 2026, 04:49 UTC

Utili

Analysts Saw Santander 1Q Rev EUR15.00B

29 apr 2026, 04:49 UTC

Utili

Santander 1Q Rev EUR15.14B

27 apr 2026, 09:32 UTC

Discorsi di Mercato

Utili

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 apr 2026, 09:19 UTC

Discorsi di Mercato

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 apr 2026, 05:34 UTC

Utili

Sanofi: 2026 Expectations Are at Constant Exchange Rates

Confronto tra pari

Modifica del prezzo

Sanofi SA Previsione

Obiettivo di Prezzo

By TipRanks

28.18% in crescita

Previsioni per 12 mesi

Media 93.7 EUR 28.18%

Alto 107 EUR

Basso 80 EUR

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

10 ratings

4

Acquista

6

Mantieni

0

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Sanofi SA - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

91.3 / 96.1Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

118 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Altri titoli del settore

SRT3

Sartorius AG

215.05

ORNBV.FI

Orion Oyj (Class B)

68.55

PHMA

Pharma Mar SA

95.6

DRW3

Draegerwerk AG & Co KGaA- PREF

89.85

Live chat